Dept of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Univ Brest, Brest, France.
Eur Respir J. 2020 Jun 25;55(6). doi: 10.1183/13993003.00189-2020. Print 2020 Jun.
Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe long-term complication of acute pulmonary embolism (PE). Untreated CTEPH is fatal, but, if diagnosed in time, successful surgical (pulmonary endarterectomy), medical (pulmonary hypertension drugs) and/or interventional (balloon pulmonary angioplasty) therapies have been shown to improve clinical outcomes, especially in case of successful pulmonary endarterectomy. Early diagnosis has however been demonstrated to be challenging. Poor awareness of the disease by patients and physicians, high prevalence of the post-PE syndrome ( persistent dyspnoea, functional limitations and/or decreased quality of life following an acute PE diagnosis), lack of clear guideline recommendations as well as inefficient application of diagnostic tests in clinical practice lead to a reported staggering diagnostic delay >1 year. Hence, there is a great need to improve current clinical practice and diagnose CTEPH earlier. In this review, we will focus on the clinical presentation of and risk factors for CTEPH, and provide best practices for PE follow-up programmes from expert centres, based on a clinical case.
慢性血栓栓塞性肺动脉高压(CTEPH)是急性肺栓塞(PE)最严重的长期并发症。未经治疗的 CTEPH 是致命的,但如果及时诊断,成功的手术(肺动脉内膜切除术)、药物(肺动脉高压药物)和/或介入(球囊肺动脉成形术)治疗已被证明可以改善临床结果,尤其是在肺动脉内膜切除术成功的情况下。然而,早期诊断已被证明具有挑战性。患者和医生对该病的认识不足、PE 后综合征(急性 PE 诊断后持续呼吸困难、功能受限和/或生活质量下降)的高患病率、缺乏明确的指南建议以及诊断测试在临床实践中的应用效率低下,导致报告的惊人诊断延迟>1 年。因此,迫切需要改进当前的临床实践并更早地诊断 CTEPH。在这篇综述中,我们将重点关注 CTEPH 的临床表现和危险因素,并根据临床病例提供来自专家中心的 PE 随访计划的最佳实践。